The Top 5 Biosimilars Articles for the Week of March 5
The Center for Biosimilars recaps the top 5 biosimilars articles for the week of March 5, 2018.
Transcript:
Hi, I’m Laura Joszt for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.
Here are the top 5 biosimilars articles for the week of March 5.
Number 5: Michigan has become the latest state to enact legislation governing the pharmacy-level substitution of interchangeable biosimilars.
Number 4: Dr Gillian Woollett, of Avalere Health, told The Center for Biosimilars® that the United States does not have to reinvent the wheel on biosimilar safety, but can learn from international experience.
Number 3: A systematic literature review shows that switching to a biosimilar carries only a low risk of safety concerns or loss of efficacy.
Number 2: Samsung Bioepis’ Ontruzant launched in the United Kingdom this week as the first biosimilar trastuzumab to enter the European market.
Number 1: Dr Scott Gottlieb, Commissioner of the FDA, said in remarks delivered at the National Health Policy Conference of America’s Health Insurance Plans that the economics of biosimilar development in the United States are "currently unstable."
Finally, last week, our e-newsletter asked for your thoughts on whether the FDA should levy fines against research entities that fail to disclose their clinical trial data.
To view results of the poll, visit us on LinkedIn.
To read all of these articles and more, visit centerforbiosimilars.com.
Biosimilar Business Roundup for October 2023—Podcast Edition
November 5th 2023On this episode, we discuss the biggest news to come out of October 2023, including 3 regulatory approvals, 2 complete response letters, and new data and industry insights that have the potential to impact the entire US biosimilar industry.
IQVIA Highlights Opportunity to Cash In on Biosimilars for Biologics Losing Market Exclusivity
November 29th 2023A report from IQVIA noted that Europe could miss out on €15 billion in cost savings by not having biosimilars for medications about to lose market exclusivity, shedding light on the implications for overall health care savings and ultimately, patient access.
Biosimilars Regulatory Roundup for September 2023—Podcast Edition
October 1st 2023On this episode, we discuss several regulatory updates from around the globe, including some European and Japanese approvals, the FDA’s 2-day workshop on the present science behind clinical efficacy testing for biosimilars, and streamlining biosimilar development.
CVS Caremark Switches Up Biosimilar Coverage in 2024
November 27th 2023As new biosimilars are added to CVS Caremark’s standard formulary, others are removed. One notable change is with the Humira biosimilars: the pharmacy benefit manager has removed Amjevita in favor of Hyrimoz and an unbranded biosimilar.
